N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
N/A N=25 Diet and Systemic Inflammation
Low-grade Chronic Inflammation · Intestinal Permeability · Type 2 Diabetes Mellitus
Primary: Fasting Plasma C-reactive Protein — 0.91; 1.07; 1.67; 1.09 mg/L — p=0.403
Phase 3 N=123 Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Vascular Inflammation · Atherosclerotic Cardiovascular Disease
Primary: Change in Arterial Inflammation — 0.03; 0.20 percent change
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
N/A N=74 Lipids, Inflammation, and CV Risk in RA
Rheumatoid Arthritis · Cardiovascular Disease
Primary: Coronary Flow Reserve — 2.65 ratio
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
N/A N=20 Acupuncture for Reduction of Inflammation
Thyroid or Parathyroid Surgery
Primary: Reduced Pain Medication Requirement — 5.43; 7.36 mg of Morphine
N/A N=64 Effect of Inflammation on Pharmacokinetics of Posaconazole
Mycoses
Primary: C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L — 1.8; 23.5 mg/L — p=0.77
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Phase 3 N=58 Inflammation and Vascular Function in Atherosclerosis
Atherosclerosis
Primary: Flow-mediated, Endothelium-dependent Vasodilation — 6.8; 8.7 percentage vasodilation
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 2 N=10 SP16 Inflammatory Response Inhibition Trial
Myocardial Infarction · Inflammation
Primary: Area Under the Curve (AUC) for C-reactive Protein (CRP) — 133 mg*day/L
Phase 3 N=20 Sitagliptin Therapy and Kinetics of Inflammatory Markers
Type 2 Diabetes Mellitus
Primary: Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period
N/A N=10 Anti-inflammatory Effects of the Fiber
Type 2 Diabetes
Primary: Peak Change in From Baseline in Reactive Oxygen Species (ROS) Generation — 224; 167 percentage of change
Phase 2 N=60 Imaging Inflammation in Alzheimer's Disease
Alzheimer's Disease
Primary: 11C-PBR28 Binding — 1.25; 1.15; 1.16; 1.02 SUVR
Phase 2 N=10 Inflammation, Polyphenols, and Genetics
Overweight · Obese
Primary: Serum IL-6 — 42.4; 34.3 (pg*hr)/mL
Phase 4 N=54 The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
Type 2 Diabetes · Diabetes
Primary: Change in Fasting Plasma Glucose Concentration — 4.7; 0.0 mmol/l
Phase 2 N=45 Targeting Inflammation to Treat Cardiovascular Aging
Vascular Stiffness · Endothelial Dysfunction · Diastolic Dysfunction
Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec
N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
Phase 2 N=25 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 4 N=29 Fish Oils and Adipose Inflammation Reduction
Obesity
Primary: Change in Plasma Fractalkine Levels — 0.42; 0.46; 0.48; 0.45 ng/ml
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Phase 3 N=63 Enhancing Adaptations to Exercise
Inflammation
Primary: Change in Maximum Workload Muscle Strength — 7.5; 3.1 pounds
Phase 2 N=16 SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity · Pre-diabetes
Primary: Change in Adipose Pro-inflammatory T Helper Type 1 Cell Percentages After 3 Months — -1.6 Percentage of CD3+ T cells
Phase 4 N=49 Compare Anti-inflammatory Dentifrices
Gingivitis
Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05
Phase 4 N=280 Anti-inflammatory Effects of Colchicine in PCI
Coronary Artery Disease
Primary: Percent Change in Post-procedural IL-6 Concentration From Baseline to 30 Min -1 hr After PCI — 0; 20 % change — p=0.31
N/A N=9 Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes
Pre-Eclampsia · Pre-Term · Intrauterine Growth Restriction
Primary: Blood Pressure (mmHg) — 122; 116 mmHg